ArticleLife (Basel, Switzerland)2025
MMP-2-Potential Predictor of Epithelial-Mesenchymal Transition in Squamous Cell Carcinogenesis.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sotagliflozin, a Dual SGLT1/2 Inhibitor, Modulates DNMT1 and Class I/II HDAC Expression in Association With Anticancer Effects in Breast and Lung Cancer Cells.Cell biology international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial-mesenchymal transition (EMT) is one of the key steps in cutaneous carcinogenesis. At the molecular level, this cellular dedifferentiation is modulated by the interaction of signalling pathways that favour basement membrane degradation under the influence of proinflammatory cytokines and matrix metalloproteinases (MMPs). Given the intricate role of these endopeptidases in modulating extracellular matrix turnover, the present study aimed primarily to identify the MMP-2 expression profile during the early stages of cutaneous malignant transformation. Forty-eight lesions with malignant transformation potential were excised in healthy tissue. Following the histopathological diagnosis of keratoacanthoma, Bowen's disease and actinic keratosis, the biological preparations were deparaffinised and homogenised in order to perform the FRET technique using the "MMP-2 Assay Kit Fluorometric". The results of the previous part of this research indicate that MMP-2 expression is more intense in lesions of actinic keratosis compared to normal tissues and to keratoacanthoma or Bowen's disease lesions, inversely proportional to the histopathological degree of dysplasia. Monitoring metalloproteinase activity in dysplastic epithelium may improve the detection of malignant transformation and guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.